Constipation: why more fibre is often not the answer

You are sitting on the toilet in the morning and you already have the feeling that this will take a while. You push. You wait. At some point you get up because time is short, and you carry that half finished feeling with you all day.

And you are actually doing everything the way you were told. More fibre. More water. More movement. Maybe for months.

Many people know this pattern. The advice was well meant, it was not wrong, and it still changed nothing. Some even report that their belly has been fuller since the change than it was before.

So I do not start with home remedies. You will not get a list of twenty tips here, eighteen of which you already know. You get the question that comes before every tip.

That question is: which kind of constipation is actually present. There are at least three, and they behave differently. With the first one, fibre is usually the right first step. With the second, usually not. And with the third, the one most often overlooked, there is a training procedure that performed clearly better in randomised trials than the most commonly used medicine.

The pleasant part: I do not have to argue against the guideline anywhere for this. The German S2k guideline on chronic constipation from 2022 says almost everything in this article itself. It has simply barely arrived anywhere yet. Where this text goes beyond the guideline, I say so.

What constipation actually is, and why frequency is the weakest marker

The first question in the consultation is almost always the same: is this even constipation.

Many people have a number in their head. Three bowel movements per week, below that it counts, above it does not. That number really is in the definition. It is just one of six criteria, and of all things the weakest one.

The German S2k guideline of the DGVS and the DGNM phrases it in statement 1-1 almost word for word like the international Rome IV criteria. Chronic constipation is present when at least two of six features have persisted for at least three months, each in more than a quarter of bowel movements. Onset should be at least six months ago.

Why is the definition built this way. Because the guideline itself argues in its commentary that transit time is linked more to consistency than to frequency. And exactly that can be measured.

This scale is not a pretty extra for medical practices. It was validated in Bristol in 1997, and in a way you rarely see: the researchers deliberately changed transit time and looked at which marker moved with it.

That leaves the question of how common this actually is. For Europe the guideline names a mean prevalence of around 15 percent. A German internet survey with 15,002 participants found 14.9 percent in the previous twelve months and 2.5 percent at the time. Another number from the same survey stands out: 4.4 percent were taking laxatives, but only 2.6 percent had ever seen a doctor about it.

The last number is the one that occupies me. Most people with chronic constipation never talk about it. They sort it out alone, with whatever the chemist has on the shelf, and many of them sort it out past the mechanism. Not because they are being unreasonable, but because nobody ever told them that there are several mechanisms.

The three types, and why this distinction shapes everything that follows

Imagine a route along which something is being transported. There are exactly three ways a route can stall. The route itself is slow. Or the route is fine, but the gate at the exit is jamming. Or everything runs at normal speed and it still feels wrong.

That is exactly how it is in the bowel. The guideline names these three explicitly in recommendation 3-4b as the targets of further diagnostics: slow transit constipation, defecatory disorder and normal transit constipation. They are not there as an academic nicety, but because treatment is decided by them.

Type 1: everything on schedule, still hard work

In normal transit constipation, transit time is unremarkable. People with this type still report hard stools, straining and a sense of unfinished business. Part of that lies in perception: the abdomen reports back more strongly than the measured value would suggest.

That is why this type overlaps so strongly with irritable bowel syndrome. The meta-analysis by Suares and Ford found an odds ratio of 7.98 for both pictures being present at the same time. That is no coincidence, but a pointer to shared mechanisms. If abdominal pain is in the foreground for you, the IBS article is the better entry point. A temporary reduction of certain carbohydrates can be one route with this overlap, and everything on that is in the article on the FODMAP diet and how to apply it properly.

Type 2: the route itself is slow

In slow transit constipation the content takes measurably longer through the large bowel. The longer it is on the way, the more water is drawn out of it, and the harder it becomes. That explains why with this type the form slides downwards, towards Bristol 1 and 2.

What lies behind it is honestly not yet fully settled. In statement 2-4 the guideline describes various changes that have been found in people with this form: a reduced number of interstitial cells of Cajal, that is, the pacemaker cells of the bowel musculature, as well as changes in the enteric nervous system. It states explicitly, though, that these findings are associated with the disorder without causality being established. That is an important restraint, and it suits the guideline well.

Type 3: the pelvic floor that shuts

Now to the type that appears in practically no German guide and that occupies me most in the consultation.

For evacuation to work, two things have to happen at the same time. Pressure in the abdomen rises, and the pelvic floor lets go. This is a coordinated interplay, similar to speaking, where breathing out and the vocal folds have to work together. In pelvic floor dyssynergia the opposite happens: the pelvic floor tightens during straining, or it relaxes too little. Sometimes the necessary pressure build up is simply missing.

Rome IV defines this functional defecation disorder cleanly and with three objective tests: an abnormal evacuation pattern on manometry, an abnormal balloon expulsion test, or impaired evacuation on imaging. Two of three have to be positive. That is exactly why this diagnosis is not reliably made without functional testing.

I write this deliberately as signs of suspicion and not as a self test. None of them proves anything. They are the reason to ask a particular question at your next appointment, namely whether anorectal functional testing would make sense.

One pointer on telling things apart, before you think of the pelvic floor: the same complaints can also come from something sitting right at the exit. An anal fissure, a small tear, causes pain on passing stool, holding back, straining and an incomplete feeling. Haemorrhoids, a rectocele and a bulging of the rectal wall can feel very similar. All of that is seen and felt in a few minutes. That is why inspection and the rectal examination come first and not functional testing. More on this in the article on haemorrhoids and anal complaints.

How the three are told apart, and where the limits lie

The guideline is clearer here than many expect. Under recommendations 3-1a and 3-1b, basic assessment includes not only history taking but also physical examination with inspection of the anus and digital rectal examination, explicitly including assessment of resting tone, squeeze pressure and a simulated defecation. Plus a stool diary with the Bristol scale.

This rectal examination is the most important first step because it is the cheapest one. But it has a limit, and that limit is in the same guideline: its negative predictive value for a defecatory disorder is around 64 percent. An unremarkable examination therefore does not reliably rule it out. Anyone who shows the signs above despite an unremarkable examination has good reason to keep asking.

Before you now think of an appointment at a specialist clinic: the guideline does not place this functional testing at the beginning. It sits at the second stage, that is, after a treatment attempt that achieved nothing, or in the presence of warning symptoms. That is not bureaucracy, it is good sense. Most people with constipation never need it.

Why fibre does not reach the wrong types

There is a sentence I often hear in the consultation, and it sounds almost apologetic: but I already eat so many vegetables.

Behind it sits an assumption that everyone shares. Constipation arises from too little fibre, so it goes away with more of it. This assumption is so widespread that it is barely noticed as an assumption any more.

The German guideline sees it in a more differentiated way, in one of the most important sentences of the whole document. Statement 2-1 records that associations between constipation and a low fibre diet, reduced fluid intake, lack of movement and suppression of the urge to defecate have indeed been described, but that a direct causal link is not established. In the commentary the sentence is even clearer: people with constipation do not consume less fibre than people without.

And then there is a study that explains the rest. It is nearly thirty years old, it comes from Munich, and it is the reason for the headline of this article.

So that this does not stand as an isolated finding: what do the pooled data say. There are three relevant meta-analyses, and together they paint a very consistent picture.

The fair counter argument, and why the guideline still recommends 30 grams

You could now build an anti fibre manifesto out of this. That would be wrong, and the guideline shows why.

In 5-1 it continues to recommend aiming for 30 grams of fibre per day, just as for the general population. And in statement 5-2 it rates fibre supplements as a sensible first strategy. The reasoning for that is remarkably sober: easy to implement, inexpensive and, in the guideline's assessment, low risk. What that means in the individual case and where the limits lie is set out just below. That is not a statement about effect size, but about the ratio of effort, risk and possible benefit. And in that calculation fibre comes off well.

Everything else about fibre, the number 30, soluble versus insoluble fibre, the role in diverticular disease: that is covered in detail in the article on fibre myths and what holds up. Here it is only about the consequence specific to constipation.

The secondary causes that belong in assessment

There is a group of people for whom the whole discussion of types misses the point. For them constipation is not the starting point but the consequence of something else. And that something else is often surprisingly close at hand.

In statement 2-3 the guideline sorts this into three groups: medicines, plus neurological, endocrine and systemic conditions. I will start with the group I consider practically the most important, because it is often overlooked and because it can be checked comparatively easily.

Medicines: the list that belongs on the note

The thyroid, with the honest nuance

Hardly any link is named as often as this one. And it does hold: an underactive thyroid can encourage constipation. It is just more precise than it is usually told.

In the commentary on statement 2-3 the German guideline writes three things that together give a different picture. First: endocrine causes are on the whole rather rare. Second: in hypothyroidism, studies showed no prolonged gastrointestinal transit time but an altered sensitivity in the rectum. Third: among people with constipation and no other clinical pointers to an underactive thyroid, one is in fact only very rarely present.

The large review by Müller-Lissner and colleagues comes to the same result: an underactive thyroid can cause constipation, but among people presenting with constipation it is rare. TSH therefore belongs in targeted assessment when other signs are present, and not as a reflex in every basic workup.

If a thyroid condition is known in your case, constipation still belongs in the conversation. What nutrition can contribute in this context is covered in the article on nutrition in Hashimoto. Existing thyroid medication stays unchanged unless something else has been agreed medically.

Metabolism, electrolytes, nerves, pregnancy

Diabetes. A long standing disorder of sugar metabolism can affect the nerve supply of the bowel and slow passage. This belongs to the systemic causes in the guideline.

Calcium and potassium. A raised calcium level and a low potassium level can make the bowel musculature more sluggish. Both are simple laboratory values, but under the guideline they belong in targeted rather than blanket assessment.

Neurological conditions. The commentary on statement 2-3 records that diseases of the central or peripheral nervous system can secondarily lead to slowed transit and disturbed anorectal evacuation. In Parkinson disease this is particularly well described, and there constipation often precedes the motor signs by years. Multiple sclerosis and spinal cord injury also belong in this group.

Pregnancy. A progesterone related slowing of passage has been described. What the guideline adds is interesting: between pregnant women with and without constipation, no significant hormone differences were found. So the hormone explains the direction, but not the difference between the women. For treatment in pregnancy the guideline names macrogol first, because it is not absorbed. Lactulose, sodium picosulfate and bisacodyl also come into question. Plant anthraquinones such as senna, by contrast, are not first choice in pregnancy and breastfeeding and should not be taken there on your own initiative. The same applies to saline magnesium compounds. Which agent fits your situation belongs in a medical conversation in every individual case, and in pregnancy and breastfeeding especially so.

Coeliac disease. It shows itself more often with diarrhoea, but it can also come with constipation. One pointer that matters more in this context than any statistic: a gluten free diet before testing can make the diagnosis impossible, because antibodies and tissue findings are then no longer informative. Anyone with this suspicion gets tested first and changes their diet afterwards, not the other way round. How the diagnostics work in detail is covered in the article on recognising coeliac disease and assessing it properly.

And how broadly should one search

Here the paths part, and that belongs said openly.

The German guideline is reserved. The commentary on recommendation 3-1a states that there are no reliable data showing that blood count, thyroid function or serum calcium are useful as basic assessment when there are no red flags and no pointers to an underlying condition. Only with warning symptoms or after an unsuccessful treatment attempt does the full programme follow: blood count, inflammatory markers, targeted electrolytes, kidney values, liver and pancreatic enzymes, TSH, blood glucose and HbA1c, calprotectin, plus abdominal ultrasound and ileocolonoscopy.

This restraint has good reasons, and I find them understandable. Every value determined without a question produces, with a certain probability, a borderline finding which then wants assessing in its own right. That costs time, money and nerves, and at the end there is often nothing.

Where I proceed a little differently in my practice from the letter of the guideline, I say so: with chronic digestive complaints I look at a few basic values earlier, because I see people who already have several stations behind them. That is a practice decision in the individual case and not a study based recommendation. The guideline has good arguments for its restraint, and anyone who follows it does nothing wrong.

Methane and slow transit, briefly

One mechanism behind the slow transit type deserves its own mention, even though it only forms the bridge here.

Certain microorganisms in the gut, more precisely methane producing archaea, produce methane. On the current understanding, methane can slow passage in the bowel, but this connection is not yet established in humans. It is discussed as one of the possible routes by which an unremarkable bowel can become a slow one. What follows from it therapeutically is likewise still open and belongs in medical hands.

I will leave it at these few sentences here, because there is an article of its own on it, in which the breath test, the thresholds and the treatment approaches under discussion are set out in full and with sources: methanogenic gut bacteria, IMO and constipation.

One sentence to draw the line: bacterial overgrowth of the small intestine, SIBO for short, is something different and comes more often with diarrhoea and bloating, and everything on that is in the article on SIBO in the small intestine.

The tools and what they can do

Now it gets concrete. And because it gets concrete, one sentence comes first, and I mean it seriously: what follows are substance classes with their evidence, not a recommendation for you personally. There are no doses for you in it, only the doses that were used in the studies. Long term use of laxatives belongs under medical supervision, and anyone already taking something does not change it on their own.

A second sentence up front, because it carries the whole section: all the substances named here are available in Germany from a pharmacy without prescription. Without prescription does not mean harmless. Each one comes with contraindications, adverse effects and interactions, they are in the package leaflet and can be discussed at the pharmacy or in the practice. I name the most important ones where each substance appears, and that selection is not complete.

Macrogol, the best studied agent

Macrogol, also called polyethylene glycol, binds water in the bowel and is itself neither absorbed nor metabolised by bacteria. It passes through the bowel unchanged and takes water with it. The effect therefore rests essentially on physics and not on an intervention in metabolism. That does not make it harmless for everyone: with suspected bowel obstruction, with a perforation in the digestive tract and with severe inflammatory bowel disease it must not be used. And electrolyte free preparations do not have the same profile as electrolyte containing ones with longer use.

In recommendation 7-1a the German guideline lists it together with sodium picosulfate and bisacodyl as a first line medicine. The joint 2023 guideline of the American societies AGA and ACG gives macrogol a strong recommendation, and fibre only a conditional one. That is a ranking which practically every consumer guide reverses.

Which of these agents comes into question for you, in what amount and over what period, is still not a question an article can answer. It belongs in a medical conversation, and an ongoing treatment is discussed there and not changed on your own.

The commentary on recommendation 7-3a contains a detail that explains many complaints: because lactulose is fermented in the large bowel, it loses effect as passage time increases. So with exactly the type in which passage takes especially long, it works least well and produces the most gas doing so. If your belly became fuller on lactulose, that was no coincidence.

Magnesium, between a good trial and guideline based restraint

Magnesium has a good reputation in this field and an unusual evidence base.

The explanation sits in recommendation 7-4. The guideline calls saline laxatives such as magnesium hydroxide or Epsom salt explicitly effective, but advises rather against them because of possible adverse effects. On overdosing, magnesium intoxication threatens, up to bowel standstill or kidney failure. In heart or kidney insufficiency their use is problematic. The American guideline also rates magnesium oxide only as conditionally recommended. So this is not about a lack of effect, but about the safety margin. Which is exactly why this is not a decision for a grab at the chemist shelf: whether a saline magnesium comes into question for you at all belongs clarified medically beforehand, especially if heart or kidneys are involved or if you are already taking other agents. You do not change existing medication on your own because of this.

One misunderstanding I want to straighten out here. The laxative property runs through osmotically active, poorly absorbed magnesium salts. That is a completely different question from which magnesium form is suitable for correcting a deficiency. Anyone who wants to read up on the logic of forms will find it in the article which magnesium is the best. The dose that has a laxative effect is not the dose that fills up a deficiency.

Stimulant agents, and the myth of the lazy bowel

Now comes the part that in my experience relieves most people.

Almost everyone has heard the sentence: do not take laxatives for too long, otherwise the bowel becomes lazy and will not get going without them. This sentence appears in package leaflets, in pharmacy brochures and on a great many advice pages. I held it to be plausible myself for years.

On this, the German S2k guideline writes literally in recommendation 7-1a: limiting the period of use is unfounded.

Where does that statement come from. The basis is a 2005 review by four leading authors in the field who systematically examined the widespread assumptions. Their findings on stimulant laxatives can be summarised in four points.

On the plant based anthraquinones, that is, senna and its relatives, recommendation 7-2 says they should be considered. Habituation to sennosides appears to be very rare, although systematic studies on this are lacking. The dark discolouration of the bowel lining that can occur with prolonged use, called pseudomelanosis coli, is classified by the guideline as functionally insignificant and reversible. Here too the frame of this whole section applies: whether and for how long such an agent makes sense for you belongs under medical guidance, and anyone already taking something neither stops it nor changes the dose because of this.

Psyllium, wheat bran and the foods in comparison

If fibre, then which. The 2022 meta-analysis found significant effects for psyllium and pectin, not for every fibre type across the board. Coarse wheat bran did not perform comparably in these analyses. That fits the everyday experience of many people that bran tends to inflate the belly rather than move anything.

I find two comparative studies more interesting, ones that set foods against supplements.

Movement and drinking volume, honestly calculated

These two sit at the top of every guide. The guideline places them considerably more cautiously, and I find the reasoning convincing.

Alongside that, the guideline has three very precise recommendations. In 4-2a: physical inactivity should be avoided. In 4-2b: a therapeutic effect of physical activity beyond the age appropriate level should not be held out as a prospect. And in 4-2c: in obesity, increased activity can make sense.

Translated: getting off the sofa is documented as sensible. Going from five to seven training sessions in order to get digestion going is not. And anyone who already runs regularly and still has constipation does not have a movement deficit but an unsettled question of type.

With drinking volume it is similarly clear. An older randomised trial in 117 people suggested that an additional 2 litres of mineral water on top of a diet with about 25 grams of fibre strengthens the effect of the fibre on stool frequency and laxative use. The work comes from a journal that has since been discontinued, so it stands here as a pointer and not as a load bearing piece of evidence. In 4-1a and 4-1b the guideline draws the practical conclusion from this: aim for 1.5 to 2 litres a day, and intake beyond that has no therapeutic effect and should not be recommended.

What is deliberately not in this section: probiotics, because that is a field of its own with its own evidence and is covered in detail in the article on probiotics in spore form or capsule. And dietary protocols with an exclusion and reintroduction phase, because they belong in the FODMAP article and not here.

Toilet habits, posture and timing

There is an area hardly anyone talks about, because it is uncomfortably concrete: how you actually sit on the toilet and when you go.

The evidence on this is thinner than the tone in which it is written about suggests. So with every point I say how firm the ground is.

Posture, and the honest counter check

The idea is simple. In a squat, the angle between rectum and pelvic floor sits more favourably, and the muscle that normally kinks the rectum gives way more. A footstool in front of the toilet is the obvious approximation to that.

In healthy people the effect is clearly measurable. In an Israeli comparative study of 28 volunteers, both the time needed and the subjectively rated effort were markedly lower in the squatting position than in either sitting position, in all participants. An American cross over study of 52 volunteers recorded 1,119 bowel movements and found, with a footstool, a better sense of complete evacuation with an odds ratio of 3.64, less straining with an odds ratio of 0.23 and a shorter duration.

The window after eating

After a meal, tone in the large bowel rises. This gastrocolic reflex is not folk wisdom but measurable. A Dutch working group examined it with a barostat in 33 volunteers: after a meal of 600 kilocalories, the measured volume fell by 28 percent within an hour.

Two details from the same work belong with it. First, only 64 percent of the healthy volunteers showed a meal response at all. Two thirds, then, not everyone. Second, doubling to 1,000 kilocalories did not strengthen the response significantly. So a bigger breakfast is not a solution.

And now the placement I consider important: there is no randomised trial showing that a planned trip to the toilet after breakfast improves chronic constipation. The reflex is documented, its therapeutic use is clinical tradition. It costs nothing, it does no harm, and it is worth a try. I am not allowed to sell it as a proven measure.

The guideline is similarly cautious about suppressing the urge to defecate. Recommendation 4-3 advises avoiding regular suppression. The commentary on it is remarkably open: two weeks of deliberate suppression prolongs colonic transit in healthy people, whether regular suppression promotes chronic constipation remains unclear.

The pelvic floor learns

There is a thought I want to phrase carefully, because it is sensitive.

The pelvic floor is musculature that reacts both voluntarily and involuntarily. It reacts to tension, to hurry, and to whether a situation is experienced as safe. An international review from 2009 treats holding back stool as learned behaviour and also addresses distressing experiences as a possible factor in the development of defecatory disorders.

I write this explicitly as a pointer, not as an attribution. It is a review article and not a causality study. No person with a defecatory disorder should conclude from it that something is wrong with them. What follows from it is something friendlier: if a muscle has learned something, it can also learn something else. And if distressing experiences are in the room, professional support is the right place for that, not self interpretation. How closely gut and nervous system are connected is set out in detail in the article on the gut brain axis and the vagus nerve.

Biofeedback, the strongest intervention evidence in the field

If you have read this far and recognise yourself in the signs of a defecatory disorder, this is the most important section of the whole article.

Biofeedback sounds like esotericism and is the opposite of it. A probe measures what the pelvic floor does during straining and makes it visible on a screen. Anyone who sees that they are tightening while believing they are letting go can change that. That is exactly what is practised, in a few sessions, together with building the right abdominal pressure and expelling a balloon.

Two further randomised trials answer the obvious objections.

The first objection runs: perhaps it is the attention. An American working group randomised 77 people to real biofeedback, sham feedback and standard therapy. The biofeedback group made the dyssynergia disappear more often, improved the defecation index more strongly and shortened balloon expulsion time more clearly than both comparison groups. Colonic transit improved after real biofeedback and after standard therapy, and not after sham feedback.

The second objection runs: perhaps the instruction is enough and the device is an accessory. A study from North Carolina randomised 84 people to biofeedback, a muscle relaxant as a tablet, or placebo. All three groups received the same six individual hours of pelvic floor training. Only one group additionally received the feedback. After three months, 70 percent in the biofeedback group reported adequate relief, against 38 percent on placebo and 23 percent on the muscle relaxant.

The German guideline draws clear consequences from this. Recommendation 10-1: in pelvic floor dyssynergia, biofeedback training should be carried out. Recommendation 10-2a: in pure slow transit constipation, biofeedback should not be used. Recommendation 10-2b: in a combination of both disorders it can be helpful. The meta-analysis of eight studies cited in the guideline commentary gives an odds ratio of 3.657 with a confidence interval of 2.127 to 6.290.

The guideline also names predictors. Favourable are motivation, a high anal resting pressure, a long balloon expulsion time and hard stool. Unfavourable are an anxiety disorder, an eating disorder, depression and long previous laxative use. Anyone who recognises themselves in the unfavourable predictors should not read that as a refusal, but as a pointer that the accompanying level then also needs attention.

Two practical additions. First: a simpler balloon training without device feedback was compared directly and performed more weakly, satisfaction was 52 against 79 percent. Second: an American study in 100 people compared home treatment with clinic treatment. Home treatment was not inferior and cost a median of around 830 US dollars less per person.

The red flags and when a colonoscopy is due

We have talked a lot about what can be explained harmlessly. Now comes the part where I would like you to read closely.

The vast majority of people with constipation have a functional disorder. But the question of whether something else lies behind it is not answered by gut feeling, it is answered by a list. The German guideline has this list in recommendations 3-3 and 3-4, and it is the reason this section is here.

How the guideline orders the pathway

The scheme is simpler than it sounds, and it has an inner logic.

Without warning symptoms, a treatment attempt comes first. Basic assessment is history taking and physical examination including digital rectal examination with simulated defecation, plus a stool diary with the Bristol scale. Then treatment follows and after about four weeks it is reviewed to see whether anything has changed. Routine laboratory testing explicitly does not belong at this point.

With warning symptoms or high symptom burden, further investigation follows immediately, without a prior treatment attempt. Then comes the laboratory work with blood count, inflammatory markers, targeted electrolytes, kidney values, liver and pancreatic enzymes, TSH, blood glucose and HbA1c as well as calprotectin, plus abdominal ultrasound and ileocolonoscopy.

If the treatment attempt has achieved nothing after four weeks, the same extended programme applies. And only after that, at the second stage, comes functional testing with anorectal manometry, balloon expulsion test, imaging and a colonic transit study.

I find this order sensible, and I gladly defend it against the impulse to investigate everything at once. It has just one precondition: the treatment attempt has to match what is actually there. If someone with a defecatory disorder raises their fibre intake for four weeks, then after those four weeks it is not the constipation that is treatment resistant, the attempt was aimed past the mechanism.

That leaves a summing up. Constipation is one word for at least three different processes. With one of them a fibre trial is the obvious first step and has a high success rate. With the second, passage itself takes too long, and there osmotic and stimulant agents are the better documented tools, under medical supervision. With the third, the exit closes instead of opening, and there a training procedure performed better in the available randomised comparisons than macrogol, than a muscle relaxant and than sham feedback. It has not been tested against the newer prescription only substances. The real hurdle is finding access to it at all.

On top of that comes the question of secondary causes, above all the medication list, which easily slips through between two appointments in everyday practice because it takes time. And above all of it lies the safety level with the red flags, which overrides everything else.

If you want to place the whole picture, how digestion, microbiome and symptoms hang together, the article on the holistic gut reset is the place where the individual strands of this cluster come together.

Frequently asked questions

Related reading from other areas